First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04075721

Recruitment Status : Terminated (The study was discontinued given the changed therapeutic landscape, lack of recruitment and totality of the data collected so far.)

First Posted : September 3, 2019

Last Update Posted : May 12, 2021

Sponsor:

Collaborator:

Merck KGaA, Darmstadt, Germany

Information provided by (Responsible Party):

EMD Serono ( EMD Serono Research & Development Institute, Inc. )

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Terminated
Actual Primary Completion Date :	April 1, 2021
Actual Study Completion Date :	April 1, 2021

Submission Cycle	Results Submitted to ClinicalTrials.gov	Results Returned after Quality Control Review
1	June 9, 2022

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Sanderson MP, Friese-Hamim M, Walter-Bausch G, Busch M, Gaus S, Musil D, Rohdich F, Zanelli U, Downey-Kopyscinski SL, Mitsiades CS, Schadt O, Klein M, Esdar C. M3258 Is a Selective Inhibitor of the Immunoproteasome Subunit LMP7 (β5i) Delivering Efficacy in Multiple Myeloma Models. Mol Cancer Ther. 2021 Aug;20(8):1378-1387. doi: 10.1158/1535-7163.MCT-21-0005. Epub 2021 May 27.

To Top